Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 18/20 | 0.55 |
| ▸ | MARK3 | P27448 | 3/20 | 0.55 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897556 | 1.00 | TBK1 (0.55) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL3976551 | 0.88 | TBK1 (0.51) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL3865255 | 0.88 | TBK1 (0.51) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL13898010 | 0.84 | TBK1 (0.78) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL3867536 | 0.84 | TBK1 (0.78) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL3865985 | 0.84 | TBK1 (0.78) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL13897890 | 0.82 | TBK1 (0.65) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL13898186 | 0.81 | STK17A (0.52) | TBK1MARK3MARK4STK17APDPK1 | |
| SCHEMBL3866511 | 0.81 | PDPK1 (0.68) | TBK1MARK3MARK4STK17APDPK1 | |
| Hydrochloric Acid SCHEMBL3875661 | 0.81 | STK17A (0.52) | TBK1MARK3MARK4STK17APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | claimed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | claimed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | TBK1 452/4885MARK3 909/4885MARK4 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.